Démence à corps de Lewy : voici pourquoi elle est confondue avec Parkinson et Alzheimer (et ce que ça change) - Cap Retraite

Google Actualités — « maladie de Parkinson » · 2026-05-18 · open original →

Démence à corps de Lewy : voici pourquoi elle est confondue avec Parkinson et Alzheimer (et ce que ça change) Cap Retraite

Reader summary

by xavier.grehant on 2026-05-19

Dementia & MCI Hallucinations & psychosis REM sleep behaviour disorder DAT-SPECT imaging Alpha-synuclein biology

This is a patient-facing explainer article from Cap Retraite, a French eldercare platform — not a research paper or clinical trial. It does not report new scientific findings, but it synthesises existing medical knowledge about Lewy body dementia (LBD, or démence à corps de Lewy / DCL in French) to help families and caregivers understand why it is so often mistaken for Parkinson's disease or Alzheimer's disease, and why getting the diagnosis right matters enormously.

Lewy body dementia is the third most common form of dementia, affecting an estimated 200,000 people in France alone — a figure likely underestimated because up to 67% of patients are never correctly diagnosed. The disease is caused by abnormal clumps of a protein called alpha-synuclein (the same protein implicated in Parkinson's) that form inside nerve cells, disrupting brain signalling over time. Because it shares motor symptoms with Parkinson's (slowness, rigidity, gait problems) and cognitive symptoms with Alzheimer's (confusion, disorientation), it falls through the diagnostic cracks. Key features that distinguish LBD from both are: vivid visual hallucinations appearing early (in at least 80% of patients), fluctuating alertness that can swing hour to hour, and REM sleep behaviour disorder — acting out dreams physically — which can precede other symptoms by years. Unlike Alzheimer's, significant memory loss tends to arrive late in LBD.

For people living with Parkinson's and their families, the distinction is not academic: certain antipsychotic medications that are sometimes prescribed for hallucinations or agitation are dangerous in LBD and can trigger severe, life-threatening reactions. Diagnostic tools that can help clarify the picture include DaTSCAN imaging (which measures dopamine-transporter activity in the brain), cardiac scintigraphy, and sleep studies (polysomnography). If a loved one has been diagnosed with Parkinson's but also shows early, prominent hallucinations, wildly fluctuating attention, or vivid dream-enactment during sleep, it is worth raising LBD explicitly with the neurologist — a correct label changes which treatments are safe and which must be avoided.

What this article adds

Dementia & MCI: This explainer highlights that Lewy body dementia (LBD) is misdiagnosed in up to 67% of cases because it mimics both Parkinson's dementia and Alzheimer's, and explains the clinical features that distinguish the three — particularly the earlier appearance of hallucinations and fluctuating cognition in LBD versus the later memory loss seen in Parkinson's dementia. The article underscores that misdiagnosis has direct treatment consequences, as drugs appropriate for one condition can be harmful in another.
Hallucinations & psychosis: The article identifies early, vivid visual hallucinations — present in at least 80% of LBD patients — as one of the key features that should prompt clinicians and families to reconsider a Parkinson's or Alzheimer's diagnosis. It also warns that certain antipsychotics commonly used to manage hallucinations can be severely dangerous in LBD, making correct diagnosis critical before any medication is prescribed.
REM sleep behaviour disorder: The article describes REM sleep behaviour disorder (physically acting out dreams) as an important early warning sign of LBD that can appear years before cognitive or motor symptoms — framing it as a diagnostic flag for families to bring to their neurologist, particularly when combined with fluctuating alertness or early hallucinations.
DAT-SPECT imaging: The article points to DaTSCAN (an imaging technique measuring dopamine-transporter function at synapses) as one of the tools neurologists use to distinguish LBD from Alzheimer's — relevant for Parkinson's patients whose diagnosis may need re-evaluation when prominent hallucinations or fluctuating cognition emerge.
Alpha-synuclein biology: The article explains to a lay audience that LBD and Parkinson's share the same underlying pathological process — abnormal alpha-synuclein aggregates forming Lewy bodies inside neurons — which is why the two diseases overlap clinically and why treatments effective or safe in one may not be in the other.

Contribute an improved analysis →